Patents by Inventor Meinolf Thiemann

Meinolf Thiemann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTI-SPECIFIC IMMUNE MODULATORS
    Publication number: 20230212260
    Abstract: The invention relates to the field of immunology and immuno-oncology. More specifically, the invention relates to multi-specific and bi-specific cytokine and antibody derivatives capable of cell and/or tissue targeting to locally enhance the immune response and to reduce systemic toxicity.
    Type: Application
    Filed: May 17, 2021
    Publication date: July 6, 2023
    Inventors: Meinolf Thiemann, Oliver Hill, Christian Gieffers, Katharina Billian-Frey
  • Light single-chain fusion polypeptides, encoding nucleic acid molecules and host cells
    Patent number: 11214605
    Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: January 4, 2022
    Assignee: APOGENIX AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) receptor agonist proteins
    Patent number: 11149075
    Abstract: Provided herein are specific GITR receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a GITRL-associated disease or disorder. The GITR receptor agonist proteins provided herein comprise three soluble GITRL domains and an Fc fragment. The GITR receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: October 19, 2021
    Assignee: APOGENIX AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Tim Schnyder
  • SINGLE-CHAIN CD137-RECEPTOR AGONIST PROTEINS
    Publication number: 20210246190
    Abstract: Provided herein are specific CD137 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD137L-associated disease or disorder. The CD137 receptor agonist proteins provided herein comprise three soluble CD137L domains and an Fe fragment. The CD137 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: December 21, 2020
    Publication date: August 12, 2021
    Inventors: Christian GIEFFERS, Oliver HILL, Meinolf THIEMANN, Tim SCHNYDER
  • Monoclonal anti-CD95L (cluster of differentiation 95 ligand) antibody
    Patent number: 11014991
    Abstract: The present invention relates to a specific CD95L antibody and to the use thereof in the treatment or diagnosis of diseases involving CD95L-induced signalling, e.g. cancer diseases.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: May 25, 2021
    Assignee: Apogenix AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Jaromir Sykora, Christian Merz, Tim Schnyder, Harald Fricke
  • SINGLE-CHAIN CD27-RECEPTOR AGONIST PROTEINS
    Publication number: 20210061880
    Abstract: Provided herein are specific CD27 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD27L-associated disease or disorder. The CD27 receptor agonist proteins provided herein comprise three soluble CD27L domains an and Fc fragment. The CD27 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: November 17, 2020
    Publication date: March 4, 2021
    Inventors: Christian GIEFFERS, Oliver HILL, Meinolf THIEMANN, Tim SCHNYDER
  • SINGLE-CHAIN CD40-RECEPTOR AGONIST PROTEINS
    Publication number: 20210032309
    Abstract: Provided herein are specific CD40 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD40L-associated disease or disorder. The CD40 receptor agonist proteins provided herein comprise three soluble CD40L domains and an Fc fragment. The CD40 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: October 5, 2020
    Publication date: February 4, 2021
    Inventors: Oliver HILL, Christian GIEFFERS, Meinolf THIEMANN, Tim SCHNYDER
  • Single-chain CD137-receptor agonist proteins
    Patent number: 10870688
    Abstract: Provided herein are specific CD137 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD137L-associated disease or disorder. The CD137 receptor agonist proteins provided herein comprise three soluble CD137L domains and an Fe fragment. The CD137 receptor agonist proteins are substantially non-aggregating and suitable for therapeuctic, diagnostic and/or research applications.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: December 22, 2020
    Assignee: Apogenix AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Tim Schnyder
  • Single-chain CD27-receptor agonist proteins
    Patent number: 10844108
    Abstract: Provided herein are specific CD27 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD27L-associated disease or disorder. The CD27 receptor agonist proteins provided herein comprise three soluble CD27L domains an and Fc fragment. The CD27 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: November 24, 2020
    Assignee: Apogenix AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Tim Schnyder
  • SINGLE-CHAIN LIGHT RECEPTOR AGONIST PROTEINS
    Publication number: 20200331979
    Abstract: Provided herein are specific LIGHT receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a LIGHT-associated disease or disorder. The LIGHT receptor agonist proteins provided herein comprise three soluble LIGHT domains and an Fc fragment. The LIGHT receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: June 10, 2020
    Publication date: October 22, 2020
    Inventors: Christian GIEFFERS, Oliver HILL, Meinolf THIEMANN, Tim SCHNYDER
  • Single-chain CD40-receptor agonist proteins
    Patent number: 10793616
    Abstract: Provided herein are specific CD40 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD40L-associated disease or disorder. The CD40 receptor agonist proteins provided herein comprise three soluble CD40L domains and an Fc fragment. The CD40 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: October 6, 2020
    Assignee: Apogenix AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Tim Schnyder
  • LIGHT SINGLE CHAIN MOLECULES
    Publication number: 20200247860
    Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: March 27, 2020
    Publication date: August 6, 2020
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • Single-chain light receptor agonist proteins
    Patent number: 10683332
    Abstract: Provided herein are specific LIGHT receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a LIGHT-associated disease or disorder. The LIGHT receptor agonist proteins provided herein comprise three soluble LIGHT domains and an Fc fragment. The LIGHT receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 16, 2020
    Assignee: Apogenix AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Tim Schnyder
  • Single-chain TL1A receptor agonist proteins
    Patent number: 10683338
    Abstract: Provided herein are specific TL1A receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TL1A-associated disease or disorder. The TL1A receptor agonist proteins provided herein comprise three soluble TL1A domains and an Fc fragment. The TL1A receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 16, 2020
    Assignee: Apogenix AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Tim Schnyder
  • CD27 ligand (CD27L) single-chain fusion polypeptides
    Patent number: 10640543
    Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: May 5, 2020
    Assignee: APOGENIX AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • SINGLE-CHAIN GITR-RECEPTOR AGONIST PROTEINS
    Publication number: 20200123223
    Abstract: Provided herein are specific GITR receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a GITRL-associated disease or disorder. The GITR receptor agonist proteins provided herein comprise three soluble GITRL domains and an Fc fragment. The GITR receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: January 2, 2020
    Publication date: April 23, 2020
    Inventors: Christian GIEFFERS, Oliver HILL, Meinolf THIEMANN, Tim SCHNYDER
  • ANTI-CD95L ANTIBODY
    Publication number: 20200102397
    Abstract: The present invention relates to a specific CD95L antibody and to the use thereof in the treatment or diagnosis of diseases involving CD95L-induced signalling, e.g. cancer diseases.
    Type: Application
    Filed: September 26, 2019
    Publication date: April 2, 2020
    Inventors: Christian GIEFFERS, Oliver Hill, Meinolf Thiemann, Jaromir Sykora, Christian Merz, Tim Schnyder, Harald Fricke
  • Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) agonist proteins
    Patent number: 10533043
    Abstract: Provided herein are specific GITR receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a GITRL-associated disease or disorder. The GITR receptor agonist proteins provided herein comprise three soluble GITRL domains and an Fc fragment. The GITR receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: January 14, 2020
    Assignee: Apogenix AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Tim Schnyder
  • CD40L single-chain fusion polypeptides and encoding nucleic acids
    Patent number: 10519208
    Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: December 31, 2019
    Assignee: Apogenix AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • CD27L collectin fusion proteins and encoding nucleic acids
    Patent number: 10519217
    Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: December 31, 2019
    Assignee: APOGENIX AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschaedel